{"id":512,"date":"2009-12-01T12:01:00","date_gmt":"2009-12-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/was-tun-bei-statin-unvertraeglichkeit"},"modified":"2009-12-01T12:01:00","modified_gmt":"2009-12-01T11:01:00","slug":"was-tun-bei-statin-unvertraeglichkeit","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/was-tun-bei-statin-unvertraeglichkeit","title":{"rendered":"Was tun bei Statin-Unvertr\u00e4glichkeit?"},"content":{"rendered":"<p>Zu diesem Thema erschien k\u00fcrzlich ein ausf\u00fchrlicher und informativer Review-Artikel in den Ann. Intern. Med. (1). Statine haben die Behandlung atherosklerotisch verursachter Herz-Kreislauf-Erkrankungen sehr verbessert und deren Morbidit\u00e4t und Letalit\u00e4t gesenkt. \u00dcber die gesicherten Indikationen f\u00fcr Statine, gemessen an der Reduktion kardiovaskul\u00e4rer Ereignisse bei Patienten mit und ohne Hyperlipid\u00e4mie, bei Diabetikern und Nicht-Diabetikern, haben wir [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zu diesem Thema erschien k\u00fcrzlich ein ausf\u00fchrlicher und informativer Review-Artikel in den Ann. Intern. Med. (1). Statine haben die Behandlung atherosklerotisch verursachter Herz-Kreislauf-Erkrankungen sehr verbessert und deren Morbidit\u00e4t und Letalit\u00e4t gesenkt. \u00dcber die gesicherten Indikationen f\u00fcr Statine, gemessen an der Reduktion kardiovaskul\u00e4rer Ereignisse bei Patienten mit und ohne Hyperlipid\u00e4mie, bei Diabetikern und Nicht-Diabetikern, haben wir [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[127,126,123,1047,1046,451,594,591,294,110,1048,449,491,289,329,391,1052,648,649,1051,455,453,834,643,644,456,454,1050,1049,1045,506,1043,505,443,803,802,228,1044],"class_list":["post-512","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-amiodaron","tag-antiarrhythmika","tag-antiretrovirale-therapie","tag-arzneimittelinteraktionen","tag-atorvastatin","tag-cholesterinsynthese-hemmer","tag-ciclosporin","tag-cimetidin","tag-ciprofloxacin","tag-clarithromycin","tag-coenzym-q10","tag-cse-hemmer","tag-diltiazem","tag-erythromycin","tag-fluconazol","tag-fluvoxamin","tag-gemfibrozil","tag-h2-rezeptor-antagonisten","tag-h2-rezeptoren-blocker","tag-hiv-protease-hemmer","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-imatinib","tag-itraconazol","tag-ketoconazol","tag-lipidsenker","tag-lovastatin","tag-myopathie","tag-norfloxacin","tag-q10","tag-rhabdomyolyse","tag-rosuvastatin","tag-simvastatin","tag-statine","tag-tyrosinkinase-hemmer","tag-tyrosinkinase-inhibitoren","tag-verapamil","tag-wechselwirkungen"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=512"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/512\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}